Skip to content

Wide Excision of Soft Tissue Sarcomas in Combination With Interstitial Radiation Therapy

Wide Excision of Soft Tissue Sarcomas in Combination With Interstitial Radiation Therapy in Patients With Soft Tissue Sarcomas of the Upper and Lower Extremities Compared With Postoperative Radiation Therapy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05057195
Enrollment
78
Registered
2021-09-27
Start date
2022-01-10
Completion date
2025-12-31
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma, Soft Tissue Sarcoma

Keywords

Sarcoma, Soft Tissue Sarcoma

Brief summary

Intraoperatively, in the bed of the removed tumor, a surgical mesh is sutured onto which the intrastats are fixed. On days 2-3, topometric preparation is carried out, the choice of the amount of irradiation, the calculation of the program. On the 4-5th day after the operation, a course of intra-tissue radiation therapy begins in a single dose of 3 to 5 Gy in 10 fractions 2 times a day with an interval between fractions of 6 hours, the planned total dose is from 30 to 50 Gy. (from 40 to 70 IGy). Follow-up examination after 4 weeks and then every 3 months for 24 months

Detailed description

1 day before the operation, taking blood tests: general blood test with counting the leukocyte formula and the number of platelets; biochemical blood test with the determination of indicators of liver and kidney function (including electrolytes); coagulogram; performing surgical treatment with urgent histological examination of the edge of the tumor; intraoperatively, in the bed of the removed tumor, a surgical mesh is sutured onto which the intrastats are fixed with the fixation of the outlet ends on the skin with the help of buttons. 1 day after the operation, taking blood tests: a general blood test with the calculation of the leukocyte formula and the number of platelets; biochemical blood test with the determination of indicators of liver and kidney function (including electrolytes); coagulogram. On the 2-3rd day after the surgical treatment, topometric preparation, the choice of the amount of radiation, and the calculation of the program are carried out. On the 4-5th day after the operation, a course of interstitial radiation therapy begins in a single dose of 3 to 5 Gy in 10 fractions 2 times a day with an interval between fractions of 6 hours, the planned total dose is from 30 to 50 Gy, which is equivalent to 40 to 70 IGy (isogrey). On the 6th day, removal of intrastats, on the 7th day after the operation, ultrasound of the wound and n / c vessels; assessment of the nature of wound healing. On the 10th day, discharge from the hospital.

Interventions

From 30 to 50 Gy,

RADIATIONPostoperative external beam therapy

50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin

Sponsors

Blokhin's Russian Cancer Research Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* C49.1 Malignant neoplasm of the connective and soft tissues of the upper limb, including the shoulder girdle * C49.2 Malignant neoplasm of the connective and soft tissues of the lower limb, including the hip region * Tumor size 7 cm or less * For malignant tumors: Grade 2-3 * Locally advanced soft tissue sarcomas * Absence of regional metastases * Tumor recurrence

Exclusion criteria

* Children, women during pregnancy, childbirth, women during breastfeeding. * Military personnel, with the exception of contract military personnel. * Persons with mental disorders. * Persons detained, taken into custody, serving a sentence in the form of restriction of freedom, arrest, imprisonment or administrative arrest. * The age of patients is under 18 years old * Histologically confirmed diagnosis of GIST, Kaposi's sarcoma, alveolar, clear cell sarcoma, chondrosarcoma, paraossal osteosarcoma * Inoperable tumor * A tumor with decay or with the threat of decay * The presence of damage to the skin in the affected area * The presence of a second malignant tumor * Having an active or chronic fungal / bacterial / viral infection * Uncontrolled chronic diseases of the liver, kidneys in the acute stage * Superficial tumor (within the skin) * The use of a reconstructive plastic component using a displaced musculocutaneous flap * The use of vascular prosthetics * The removed tumor bed is more than 7 cm * The presence of a tumor growing into the bone * The presence of blood vessels and nerves in the removed tumor bed * Presence of metastases * Surgical intervention using transplanted skin

Design outcomes

Primary

MeasureTime frameDescription
disease-free survival24 monthsTime after treatment during which no sign of cancer is found

Secondary

MeasureTime frameDescription
Comparison of hospitalization rate30 daysTime after surgery till the end of hospitalization
Comparison of safety assessment24 monthsAdverse Event Assessment and Serious Adverse Event Assessment according to CTCAE 5.0
Comparison of performance status according Karnofsky scale24 monthsImprovement on the Karnofsky scale by 10-30 points
Comparison of pain relief according Visual Analogue Scale24 monthsImprovement on the Visual Analogue Scale by 3-5 points
Comparison of pain relief according Whatkins scale24 monthsImprovement on the Whatkins scale by 1-2 points

Countries

Russia

Contacts

Primary ContactDenis Burov, PhD
denisburov@yandex.ru+79265585000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026